CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05138458
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:29.374820+00:00
- Published At
- 2023-11-13T00:00:00+00:00
- Record Updated At
- 2023-11-13
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell, Cutaneous", "Mycosis Fungoides", "Adoptive Cellular Immunotherapy", "Cell Therapy"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-11-13"- protocolSection.identificationModule.nctId
"NCT05138458"- protocolSection.identificationModule.officialTitle
"A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma"- protocolSection.statusModule.overallStatus
"SUSPENDED"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.